Post-radiation MR imaging features in Molecular and Mutational Analyses in Pontine Pediatric Diffuse Midline Gliomas.

Vanessa Rameh, Alireza Ziaei, Sridhar Vajapeyam, Nan Chen, Wendy B London, Karen Wright, Tina Y Poussaint
{"title":"Post-radiation MR imaging features in Molecular and Mutational Analyses in Pontine Pediatric Diffuse Midline Gliomas.","authors":"Vanessa Rameh, Alireza Ziaei, Sridhar Vajapeyam, Nan Chen, Wendy B London, Karen Wright, Tina Y Poussaint","doi":"10.3174/ajnr.A8817","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>We aimed to describe the post-radiation imaging features in children with pontine pediatric diffuse midline glioma, and to identify associations between these changes and histone mutational status, as well as overall survival.</p><p><strong>Materials and methods: </strong>Patients were recruited as part of an IRB approved, multicenter clinical trial: Molecularly Determined Treatment of pontine diffuse midline glioma. Subjects had baseline MR imaging that showed classic imaging criteria of pontine diffuse midline glioma and post radiation imaging at regular intervals. All patients underwent biopsy before therapy initiation and received standard radiation therapy with adjuvant bevacizumab. Patients were subsequently stratified based on methylation status and EGFR expression in the biopsy specimen.Imaging analyses included post-radiation T2/FLAIR and enhancing tumor volumes, as well as normalized ADC (nADC) histogram metrics (mean, median, mode, skewness, and kurtosis) at 2 and 4 months post-radiation. The mutation sub-groups were compared using a Wilcoxon rank-sum test.</p><p><strong>Results: </strong>Forty-one patients met eligibility criteria, and mutational status was identified in 35. The median age was 6 years (range: 1.2-17). Seventeen of 35 (49%) had <i>H3-3A</i> histone mutations, 10/35 (29%) had <i>H3C2/3</i>, and 8/35 (22%) were wild type (WT).Except for enhancing volume at RT2, all imaging features had a statistically significant change (p<0.05) from baseline to RT1 and RT2.Within the cohort of patients that had H3-mutant tumors (n=27), patients with <i>H3C2/3</i> had statistically significantly higher mean nADC_FLAIR (p=0.05), mode nADC_FLAIR (p=0.003), median nADC_FLAIR (p=0.02), and mode nADC-enhancement (p=0.04) than patients with H3-3A at RT1. These nADC histogram metrics were not statistically significantly different at RT2.Moreover, we found no statistically significant difference in ADC histogram metrics post radiation, when we compared H3-mutant versus WT tumors.</p><p><strong>Conclusions: </strong>Post-radiation MR imaging features are differentially correlated with the underlying mutational status of pediatric pontine diffuse midline glioma.</p><p><strong>Abbreviations: </strong>Pediatric pontine diffuse midline glioma=pDMG Diffuse intrinsic pontine glioma= DIPG Epidermal growth factor receptor=EGFR Overall survival=OS Radiotherapy=RT Progression-free survival=PFS Contrast-enhanced=CE Post-radiation time point 1 (2 months post-radiation)=RT1 Post-radiation time point 2 (4 months post-radiation)=RT2.</p>","PeriodicalId":93863,"journal":{"name":"AJNR. American journal of neuroradiology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJNR. American journal of neuroradiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3174/ajnr.A8817","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and purpose: We aimed to describe the post-radiation imaging features in children with pontine pediatric diffuse midline glioma, and to identify associations between these changes and histone mutational status, as well as overall survival.

Materials and methods: Patients were recruited as part of an IRB approved, multicenter clinical trial: Molecularly Determined Treatment of pontine diffuse midline glioma. Subjects had baseline MR imaging that showed classic imaging criteria of pontine diffuse midline glioma and post radiation imaging at regular intervals. All patients underwent biopsy before therapy initiation and received standard radiation therapy with adjuvant bevacizumab. Patients were subsequently stratified based on methylation status and EGFR expression in the biopsy specimen.Imaging analyses included post-radiation T2/FLAIR and enhancing tumor volumes, as well as normalized ADC (nADC) histogram metrics (mean, median, mode, skewness, and kurtosis) at 2 and 4 months post-radiation. The mutation sub-groups were compared using a Wilcoxon rank-sum test.

Results: Forty-one patients met eligibility criteria, and mutational status was identified in 35. The median age was 6 years (range: 1.2-17). Seventeen of 35 (49%) had H3-3A histone mutations, 10/35 (29%) had H3C2/3, and 8/35 (22%) were wild type (WT).Except for enhancing volume at RT2, all imaging features had a statistically significant change (p<0.05) from baseline to RT1 and RT2.Within the cohort of patients that had H3-mutant tumors (n=27), patients with H3C2/3 had statistically significantly higher mean nADC_FLAIR (p=0.05), mode nADC_FLAIR (p=0.003), median nADC_FLAIR (p=0.02), and mode nADC-enhancement (p=0.04) than patients with H3-3A at RT1. These nADC histogram metrics were not statistically significantly different at RT2.Moreover, we found no statistically significant difference in ADC histogram metrics post radiation, when we compared H3-mutant versus WT tumors.

Conclusions: Post-radiation MR imaging features are differentially correlated with the underlying mutational status of pediatric pontine diffuse midline glioma.

Abbreviations: Pediatric pontine diffuse midline glioma=pDMG Diffuse intrinsic pontine glioma= DIPG Epidermal growth factor receptor=EGFR Overall survival=OS Radiotherapy=RT Progression-free survival=PFS Contrast-enhanced=CE Post-radiation time point 1 (2 months post-radiation)=RT1 Post-radiation time point 2 (4 months post-radiation)=RT2.

小儿脑桥弥漫性中线胶质瘤放射后磁共振成像特征的分子和突变分析。
背景和目的:我们旨在描述小儿脑桥弥漫性中线胶质瘤的放射后影像学特征,并确定这些变化与组蛋白突变状态以及总生存期之间的关系。材料和方法:招募患者作为IRB批准的多中心临床试验的一部分:分子确定治疗脑桥弥漫性中线胶质瘤。受试者进行基线磁共振成像,显示典型的脑桥弥漫性中线胶质瘤的成像标准,并定期进行放射后成像。所有患者在治疗开始前都进行了活检,并接受了辅助贝伐单抗的标准放射治疗。随后根据活检标本中的甲基化状态和EGFR表达对患者进行分层。影像学分析包括放疗后T2/FLAIR和增强肿瘤体积,以及放疗后2和4个月的标准化ADC (nADC)直方图指标(平均值、中位数、模式、偏度和峰度)。突变亚组采用Wilcoxon秩和检验进行比较。结果:41例患者符合入选标准,35例患者存在突变状态。中位年龄为6岁(范围:1.2-17岁)。35例中有17例(49%)存在H3-3A组蛋白突变,10例(29%)存在H3C2/3组蛋白突变,8例(22%)为野生型(WT)。除RT2时体积增强外,其他影像学特征均有统计学意义的改变(pH3C2/3在RT1时nADC_FLAIR均值(p=0.05)、nADC_FLAIR模式(p=0.003)、nADC_FLAIR中位数(p=0.02)、nadc模式增强(p=0.04)均高于H3-3A患者。这些nADC直方图指标在RT2时无统计学差异。此外,当我们比较h3突变体和WT肿瘤时,我们发现放疗后ADC直方图指标没有统计学上的显著差异。结论:小儿脑桥弥漫性中线胶质瘤放射后磁共振成像特征与潜在突变状态存在差异相关。缩写:小儿脑桥弥漫性中线胶质瘤=pDMG弥漫性固有脑桥胶质瘤= DIPG表皮生长因子受体=EGFR总生存期=OS放疗=RT无进展生存期=PFS对比增强=CE放疗后时间点1(放疗后2个月)=RT1放疗后时间点2(放疗后4个月)=RT2。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信